News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,471 Results
Type
Article (39773)
Company Profile (254)
Press Release (659444)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204366)
Career Advice (2011)
Deals (35445)
Drug Delivery (95)
Drug Development (81133)
Employer Resources (172)
FDA (16189)
Job Trends (14874)
News (345504)
Policy (32560)
Tag
Academia (2555)
Accelerated approval (5)
Adcomms (21)
Allergies (85)
Alliances (49503)
ALS (89)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (128)
Approvals (16191)
Artificial intelligence (255)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11645)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (182)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (278)
Cancer (2265)
Cardiovascular disease (174)
Career advice (1678)
Career pathing (30)
CAR-T (152)
Cell therapy (424)
Cervical cancer (19)
Clinical research (66052)
Collaboration (836)
Company closure (1)
Compensation (533)
Complete response letters (19)
COVID-19 (2594)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2206)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6372)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (99)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86661)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112556)
Executive appointments (722)
FDA (17451)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (752)
Gene editing (104)
Generative AI (19)
Gene therapy (305)
GLP-1 (709)
Government (4417)
Grass and pollen (4)
Guidances (67)
Healthcare (18830)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (29)
Infectious disease (2736)
Inflammatory bowel disease (138)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (312)
IPO (16519)
IRA (40)
Job creations (3639)
Job search strategy (1424)
Kidney cancer (10)
Labor market (38)
Layoffs (469)
Leadership (17)
Legal (7911)
Liver cancer (75)
Lung cancer (320)
Lymphoma (155)
Machine learning (7)
Management (58)
Manufacturing (304)
MASH (67)
Medical device (13379)
Medtech (13384)
Mergers & acquisitions (19470)
Metabolic disorders (685)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (89)
Neuropsychiatric disorders (27)
Neuroscience (1914)
NextGen: Class of 2025 (6523)
Non-profit (4481)
Now hiring (39)
Obesity (364)
Opinion (204)
Ovarian cancer (76)
Pain (88)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (112)
Peanut (46)
People (57373)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20590)
Phase II (29088)
Phase III (21663)
Pipeline (1203)
Policy (140)
Postmarket research (2564)
Preclinical (8751)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (380)
Real estate (5920)
Recruiting (65)
Regulatory (22306)
Reports (46)
Research institute (2321)
Resumes & cover letters (350)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (131)
Series B (85)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3583)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (40)
The Weekly (29)
Vaccines (689)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (40)
Last 7 days (898)
Last 30 days (2565)
Last 365 days (32687)
2025 (10759)
2024 (35252)
2023 (40104)
2022 (51230)
2021 (55762)
2020 (54123)
2019 (46565)
2018 (35041)
2017 (32144)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26382)
2012 (28585)
2011 (29284)
2010 (27353)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (37917)
Australia (6207)
California (6143)
Canada (2020)
China (524)
Colorado (267)
Connecticut (274)
Delaware (149)
Europe (81384)
Florida (912)
Georgia (206)
Idaho (57)
Illinois (536)
India (25)
Indiana (308)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (898)
Massachusetts (4571)
Michigan (220)
Minnesota (393)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1727)
New Mexico (28)
New York (1746)
North Carolina (970)
North Dakota (8)
Northern California (2685)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1390)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (23)
South Dakota (1)
Southern California (2304)
Tennessee (101)
Texas (909)
United States (23165)
Utah (180)
Virginia (146)
Washington D.C. (62)
Washington State (552)
West Virginia (3)
Wisconsin (54)
699,471 Results for "sillajen biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
March 27, 2024
·
5 min read
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
February 12, 2025
·
6 min read
Press Releases
Adolore BioTherapeutics to Present at Festival of Biologics USA 2025
April 24, 2025
·
3 min read
Press Releases
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 7, 2025
February 9, 2025
·
1 min read
Press Releases
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
April 23, 2025
·
8 min read
Press Releases
Tavo Biotherapeutics Announces Appointment of Seasoned Executives to Key Posts
April 30, 2025
·
3 min read
Business
Mid-Atlantic BioTherapeutics, Inc. and SMITM Capital Markets Ltd enter into a significant financing agreement
SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.
June 19, 2024
·
4 min read
Press Releases
Stealth BioTherapeutics to Present New Bevemipretide Data at ARVO Annual Meeting
April 24, 2025
·
5 min read
Press Releases
Stealth BioTherapeutics Announces Delay in FDA Action Date for Barth Syndrome Application
April 29, 2025
·
3 min read
1 of 69,948
Next
